
Our track record and strength in medicinal chemistry is a key competitive advantage, enabling us to develop novel, efficacious therapeutics that function through the regulation of gene expression for the treatment of chronic disease.![]()
Stephen Shuttleworth PhD FRSC, Chief Scientific Officer
Karus Therapeutics Ltd
John Fairclough Centre
University of Southampton
Highfield
Southampton
Hampshire SO17 1BJ
United Kingdom